Vertex Pharmaceuticals (VRTX.O), opens new tab said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed little difference versus a placebo in reducing pain, sending its shares down nearly 14% premarket. https://www.reuters.com/business/he...n-goal-mid-stage-nerve-pain-trial-2024-12-19/ https://www.fiercebiotech.com/biote...nks-stock-placebo-comparison-spooks-investors